Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 10/20 | 0.36 |
| ▸ | CNR1 | P21554 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20200267 | 0.91 | MAPK1 (0.52) | MAPK1CNR2LMNAKDM4EALDH1A1 | |
| SCHEMBL10156047 | 0.80 | MAPK1 (0.37) | MAPK1LMNA | |
| SCHEMBL310962 | 0.80 | MAPK1 (0.59) | MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL13290098 | 0.73 | MAPK1 (0.51) | MAPK1LMNAKDM4E | |
| SCHEMBL13871885 | 0.72 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL12723445 | 0.72 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL14404588 | 0.71 | MAPK1 (0.54) | MAPK1LMNAKDM4E | |
| SCHEMBL14189666 | 0.67 | CNR2 (0.42) | CNR2CNR1LMNAKDM4EATM | |
| SCHEMBL13527759 | 0.67 | ADRA2C (0.35) | — | |
| SCHEMBL13899614 | 0.67 | ADRA2C (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234494-A1 | Reversibly thermochromic compositions | CIBA CORPORATION | 2010-09-16 | — | — | US | disclosed |
| US-20100048774-A1 | STABILIZER MIXTURES | GUGUMUS FRANCOIS | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234494-A1 | Reversibly thermochromic compositions | CRY1, REL, CRY2 | MAPK1 1405/4885CNR2 212/4885CNR1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.